Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer

Eitemau Tebyg

• A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay
  gan: Landi, Lorenza, et al.
  Cyhoeddwyd: (2017)
• Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?
  gan: Ruiz, Jimmy, et al.
  Cyhoeddwyd: (2015)
• Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
  gan: Stasi, Irene, et al.
  Cyhoeddwyd: (2014)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  gan: Ourania Romanidou, et al.
  Cyhoeddwyd: (2016-05-01)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  gan: Romanidou, Ourania, et al.
  Cyhoeddwyd: (2016)